Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03108495 · ClinicalTrials.gov registry record · Phase 2
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
A Phase 2 study, sponsored by Iovance Biotherapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT03108495 is a Phase 2 study that was terminated before completion, run by Iovance Biotherapeutics. The registered enrollment target is 210 participants.
The verdict
NCT03108495, a Phase 2 study, was terminated before completion, sponsored by Iovance Biotherapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma
Interventions
- BIOLOGICAL LN-145
- BIOLOGICAL LN-145 + pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2017-06-22 |
| Est. Completion | 2025-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03108495
The ClinicalTrials.gov registry entry for NCT03108495 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LN-145 is the first listed.
NCT03108495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03108495 about?
NCT03108495 is a clinical study titled "Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma". Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with...
What is the current status of trial NCT03108495?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2017-06-22. Estimated completion is 2025-08-22.
What interventions are being tested in trial NCT03108495?
The interventions under investigation include: LN-145 (BIOLOGICAL), LN-145 + pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03108495?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.